| Name | Title | Contact Details |
|---|
Innocrin discovers and develops novel, best-in-class oral inhibitors of CYP17 lyase, a validated enzyme target for the treatment of castration-resistant prostate cancer (CRPC). VT-464 and structurally-related classes of CYP17 inhibitors are wholly owned by Innocrin. CYP17 lyase inhibitors may also have high commercial potential for the treatment of breast cancer as well as non-oncologic syndromes that are due to hormonal excess including endometriosis, polycystic ovary syndrome and congenital adrenal hyperplasia.
3129 Sanofi SA is a French multinational healthcare company headquartered in Paris, France.
TubeWriter is a company that provides direct labeling systems and services to the life sciences industry. Their solutions print on any laboratory tube, slide or plate, and offer superior durability of print at extreme temperatures, up to 90% reduction ...
At DocRX we help doctors and hospitals become more efficient, and profitable. We also help make them compliant with regulations. Visit us today!